Interviews

Karen Reckamp, MD, MS, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, Department of Medical Oncology and Therapeutics Research, discusses nivolumab (Opdivo) compared to docetaxel for the treatment of patients with non-small cell lung cancer (NSCLC).

James Stevenson, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the impact of a stage IV non-small cell lung cancer (NSCLC) care pathway on frontline and maintenance chemotherapy use.

Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).

Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses a phase II study examining daratumumab for the treatment of patients with multiple myeloma.

Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.

Shannon Puhalla, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses a phase III study examining the combination of palbociclib and fulvestrant for the treatment of patients with relapsed metastatic hormone receptor-positive, HER2-negative breast cancer.

Maha H. Hussain, MD, professor of Medicine and Urology, University of Michigan, associate director, Clinical Research, co-leader, Prostate Cancer/GU Oncology Program, assistant chief, Clinical Research at the Division of Hematology/ Oncology, University of Michigan Comprehensive Cancer Center, discusses immunotherapy in prostate cancer.

Anna C. Pavlick, MD, associate professor, co-director, Melanoma Program, assistant director, Clinical Research Education, discusses a study that examined two immunotherapy agents, ipilimumab and nivolumab, in patients with melanoma.

Elizabeth Plimack, MD, MS, attending physician, genitourinary cancer associate professor, Medical Oncology Director of Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a study that examined pembrolizumab in patients with urothelial cancer.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses a phase Ia study examining atezolizumab in patients with urothelial bladder cancer.

Shirish Gadgeel, MD, Barbara Ann Karmanos Cancer Institute, discusses a phase III study examining afatinib versus erlotinib as a second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy.

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, Jefferson University Hospital, discusses the next steps following the PALOMA3 trial, which was a randomized, placebo-controlled phase III study examining palbociclib plus fulvestrant in pre- and post-menopausal patients with ER-positive breast cancer.

Joseph F. Renzulli, II, MD, FACS, assistant professor of Surgery, (Urology), Alpert Medical School, Brown University, discusses a phase II study that examined the use of abiraterone acetate with low-dose prednisone in patients with prostate cancer.

Jesus G. Berdeja, MD, director of Myeloma Research, senior investigator, Hematologic Malignancies Principal Investigator, Sarah Cannon Research Institute, discusses a phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma.

Jennifer S. Temel, clinical director, Thoracic Oncology, Massachusetts General Hospital, discusses a phase III study that examined the impact of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia.

Benjamin G. Neel, MD, faculty, Department of Medicine, Perlmutter Cancer Center, NYU School of Medicine, discusses the future of immunotherapy and how it could play a role in various tumor types.

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase 1b study examining ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine and trastuzumab in the third-line setting and treatment of HER2-positive metastatic breast cancer.

James M. Kiernan, MD, professor of Urology and director of Urologic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York, discusses EXO106, a urine assay, as a promising test for high-grade prostate cancer.

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).

Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the results of the ARIEL2 trial, a phase II study to identify patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis.

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the United States experience of the Expanded Access Program (EAP) on radium-223 for prostate cancer.

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of surgery, director, urologic oncology, University of Chicago Medicine, discusses the impact immunotherapy has had on bladder cancer.

Adam J. Bass, MD, assistant professor, Department of Medicine, Harvard Medical School, assistant professor of medicine, Division of Cellular and Molecular Oncology, Dana-Farber Cancer Institute, discusses functional genomics of Barrett's esophagus and esophageal adenocarcinoma.

Andrew T. Chan, MD, MPH, discusses using aspirin as a method of preventing colorectal cancer.

Christopher Y. Park, MD, PhD, hematopathologist, Memorial Sloan Kettering Cancer Center, discusses some of the biggest challenges in myelodysplastic syndromes (MDS).

Bart L. Scott, MD, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses breakthrough topics in myelodysplastic syndromes (MDS), such as mutational abnormalities.

Anne Marie McCarthy, PhD, research fellow, Massachusetts General Hospital, discusses a study that examined breast density, a risk that can help target breast cancer, in black women compared to white women.

Philip S. Rosenberg, PhD, senior investigator, Division of Cancer Epidemiology and Genetics, National Cancer Institute, discusses a study that examined patterns in breast cancer rates.

Charles A. (Trey) Leath III, MD, associate professor, gynecologic oncology, University of Alabama Birmingham Cancer Center, discusses a study that examined clinical outcomes and quality of life in ovarian cancer.

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses patient selection for the treatment of myeloma, especially relapsed myeloma.